Nuvation Bio
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 2 days.
- Its last 6 Sell calls were followed by roughly flat moves (-2%) three months out.
- Recent price momentum is -45.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 17.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 85.2% | Better than 94% |
| Operating margin | -338.7% | Better than 5% |
| Net margin | -325.3% | Better than 4% |
| Return on equity | -53.2% | Better than 9% |
| Return on invested capital | -50.8% | Better than 6% |
Momentum D
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -45.2% | Better than 7% |
| 6-month return | -19.5% | Better than 27% |
| 12-month return (ex latest month) | -32.8% | Better than 8% |
| Distance below 52-week high | 61.0% | Better than 10% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 7.0x | Better than 90% |
| Debt to assets | 9.6% | Better than 70% |
| Interest coverage | -14.0x | Better than 12% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 258.7% | Better than 96% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 3.81
- Open
- 3.77
- Day range
- 3.72 - 3.91
- Avg price
- 3.80
- Volume
- 6.85M
- Turnover
- 26.02M
- Turnover ratei
- 2.58%
- Volume ratioi
- 1.05
- Amplitudei
- 4.99%
- 52-week rangei
- 3.71 - 9.75
Valuation
- P/Ei
- -6.33
- P/E (TTM)i
- -9.74
- P/Bi
- 5.88
- EPSi
- -0.60
- Book value / shi
- 0.65
- Net profit
- -211.81M
- Net assets
- 228.05M
Share structure
- Market cap
- 1.34B
- Float capi
- 1.01B
- Shares out
- 353.02M
- Float sharesi
- 265.54M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
61.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-18.35M net over the window
Short interest
- Shares short
- 62.00M
- % of floati
- 17.66%
- Days to coveri
- 12.50
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Nuvation Bio (NUVB)?
Nuvation Bio last traded at 3.80. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Nuvation Bio's market cap?
About 1.34B.
What is the P/E ratio of Nuvation Bio?
The trailing twelve-month P/E is -9.74. The Valuation tab shows it against the stock's own five-year range.
Does Nuvation Bio pay a dividend?
Nuvation Bio does not currently pay a regular dividend.
Is Nuvation Bio a buy according to analysts?
The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 13.63, which implies 258.7% upside from the current price. This is not investment advice.
What is Nuvation Bio's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Nuvation Bio a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Nuvation Bio discussion 0 comments